Tirzepatide is a once-weekly injectable prescription medication that imitates two gut hormones to curb appetite and improve blood sugar control. In adults with excess fat or early blood sugar problems, strong evidence shows large, lasting fat loss, better blood sugar and lower blood pressure. The main drawbacks are digestive side effects, muscle loss along with fat, gallbladder problems and weight regain after stopping. Slower aging remains unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight and waist circumference | No established target; track percent change from own baseline | Primary response marker |
| Lean mass and bone density (DXA) | No established target; track change from own baseline | Safety check for excess lean or bone loss |
| HbA1c | 4.0–5.6% | Expected to change; low values with glucose-lowering drugs signal hypoglycemia risk |
| Fasting glucose | 70–99 mg/dL | Safety check for hypoglycemia on insulin or sulfonylureas |
| Blood pressure | No established target; track change from own baseline | Safety check for hypotension |
| Lipid panel (LDL, HDL, triglycerides) | No established target; track change from own baseline | Expected to change modestly |
| Creatinine with eGFR and urine albumin-to-creatinine ratio | Creatinine 0.6–1.3 mg/dL (sex- and laboratory-specific); eGFR and albumin-to-creatinine ratio: no established target; track change from own baseline | Safety check for dehydration-related kidney injury |
| Lipase | 0–160 U/L (laboratory-specific) | Baseline for interpreting abdominal pain |
| Heart rate | 60–100 beats per minute | Tirzepatide raises heart rate 1–3 beats per minute |
| Calcitonin (only if thyroid concern) | Below 10 ng/L (sex- and laboratory-specific) | Values above 50 ng/L suggest medullary thyroid carcinoma |
| Liver enzymes | Not specified in the ER | Baseline safety reference point |
| Grip strength | Not specified in the ER | Paired with DXA to check preserved strength |
Cadence: Baseline before starting; weight, blood pressure, and symptoms at each dose escalation (every 4 weeks); kidney function within 1–2 weeks of any vomiting or diarrhea episode; labs at 3 months, then every 6–12 months; DXA at 12 months, then every 1–2 years